Interferon-Alpha2B

DRUG2 trials

Sponsors

The Camelot Foundation, Pontificia Universidad Catolica de Chile

Conditions

CoVid 19 PositiveCoronavirus Disease 2019

Phase 1

Inhaled Interferon α2b for the Treatment of Coronavirus Disease 19 (COVID-19)

CompletedNCT04988217

Pontificia Universidad Catolica de ChileCoronavirus Disease 2019

Start: 2021-09-15End: 2022-07-28Updated: 2022-08-05

Phase 2

The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol

CompletedNCT04349410

The Camelot FoundationCoVid 19 Positive

Start: 2020-04-11End: 2020-09-14Updated: 2020-11-12

Related Papers

Safety, Tolerability, Bioavailability, and Biological Activity of Inhaled Interferon-α2b in Healthy Adults: The IN<sup>2</sup>COVID Phase I Randomized Trial.

2023-06-221 citations

Treating SARS-CoV-2 Based Upon the Fleming InflammoThrombotic Response (ITR) & Cardiovascular Disease Theory

Haematology International Journal2023-01-01